← Human Trials & Peer-Reviewed Studies
Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women
Plain-language guide to PMID 30217118 (2019): randomized controlled trial study of Teriparatide in 2016, women.
Key Facts
- PMID
- 30217118
- Journal
- Modern rheumatology
- Year
- 2019
- Study type
- Randomized Controlled Trial
- Authors
- Suzuki T et al. (3 authors)
- DOI
- 10.1080/14397595.2018.1524997
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Teriparatide, published as a randomized controlled trial.
Purpose: This extended randomized prospective study aimed to compare the 4-year clinical outcomes of denosumab treatment alone or in combination with teriparatide in treatment-naïve postmenopausal Japanese patients with osteoporosis.
Serum bone-specific alkaline phosphatase (BAP), serum tartrate-resistant acid phosphatase (TRACP)-5b, urinary cross-linked N-terminal telopeptide of type I collagen (NTX), and bone mineral density (BMD) of the lumbar 1-4 vertebrae (L-BMD) and bilateral total hips (H-BMD) were determined at the first visit and at regular time points up to 48 months of treatment to determine percentage changes.
Why It Was Studied
After newly adding 17 randomly assigned patients, 47 patients were classified into the denosumab alone group (denosumab group, n = 22) or denosumab plus teriparatide group (combination group, n = 25).
Who Took Part
According to the abstract, 2016, women were involved.
The age groups tagged for this paper are middle-aged adults and older adults, women only.
Methods: Between July 2013 and December 2016, 30 eligible women from their previous study were enrolled.
How the Study Was Run
In design terms this was a randomized study.
The women were allocated by chance, so the Teriparatide group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Bone Density, Bone Density Conservation Agents, Denosumab, Osteoporosis, Postmenopausal and Teriparatide.
The authors tagged it with the keywords Bone mineral density and combined therapy.
What This Means in Plain Language
The paper is a randomized study of Teriparatide in 2016, women.
With several hundred people or more, it is a fairly large study for this kind of research.
The publication is from 2019 (Modern rheumatology), a journal based in England.
More context: the Teriparatide compound page, all human trials.
Our Notes on the Compound
Teriparatide: A parathyroid hormone fragment, PTH(1-34), with human trials and approved-pen labeling; the research vial is not the approved pen.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.